Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

veterinary pharmaceutical companies

Pharmaceutical intelligence for veterinary pharmaceutical companies with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
0
Assets
2

Recent signals(5)

RegulatoryAugust 16, 2026

FDA Grants EUA for Simparica TRIO to Treat New World Screwworm in Dogs

The FDA has issued an Emergency Use Authorization for Simparica TRIO for treating New World screwworm infestations in dogs and puppies.

RegulatoryAugust 8, 2026

FDA Grants EUA for CLiK Extra to Combat New World Screwworm in Livestock

The FDA has issued an Emergency Use Authorization for CLiK Extra, a topical suspension for preventing New World screwworm infestations in livestock.

RegulatoryJuly 16, 2026

FDA Grants EUA for Ivermectin Liquid to Prevent New World Screwworm in Horses

The FDA has issued an Emergency Use Authorization for Ivermectin Liquid for Horses to prevent New World screwworm infestations.

ClinicalJuly 14, 2026

TACE with QS-GMP shows promise for canine lower urinary tract carcinomas

Transarterial chemoembolization using quick-soluble gelatin microparticles resulted in a median tumor volume reduction of 76.41% in dogs with lower urinary tract carcinomas.

RegulatoryJune 22, 2026

FDA Grants EUA for Nitenpyram Tablets to Treat New World Screwworm in Pets

The FDA has issued an Emergency Use Authorization for Nitenpyram Tablets to treat New World screwworm infestations in dogs and cats.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity(4)

RegulatoryAugust 16, 2026

FDA Grants EUA for Simparica TRIO to Treat New World Screwworm in Dogs

The FDA has issued an Emergency Use Authorization for Simparica TRIO for treating New World screwworm infestations in dogs and puppies.

RegulatoryAugust 8, 2026

FDA Grants EUA for CLiK Extra to Combat New World Screwworm in Livestock

The FDA has issued an Emergency Use Authorization for CLiK Extra, a topical suspension for preventing New World screwworm infestations in livestock.

RegulatoryJuly 16, 2026

FDA Grants EUA for Ivermectin Liquid to Prevent New World Screwworm in Horses

The FDA has issued an Emergency Use Authorization for Ivermectin Liquid for Horses to prevent New World screwworm infestations.

RegulatoryJune 22, 2026

FDA Grants EUA for Nitenpyram Tablets to Treat New World Screwworm in Pets

The FDA has issued an Emergency Use Authorization for Nitenpyram Tablets to treat New World screwworm infestations in dogs and cats.

Clinical activity(1)

ClinicalJuly 14, 2026

TACE with QS-GMP shows promise for canine lower urinary tract carcinomas

Transarterial chemoembolization using quick-soluble gelatin microparticles resulted in a median tumor volume reduction of 76.41% in dogs with lower urinary tract carcinomas.

Competitive activity

No signals indexed for this entity yet.

Assets

FDA →
TACE →

Therapeutic areas

Oncology →
Parasitic Infections →
Parasiticide →
Parasitology →
Veterinary →
Veterinary Medicine →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.